Article

Jessica Tinor

In June 2022, the Federal Trade Commission (FTC) launched an inquiry into the prescription drug middleman industry, requiring the largest pharmacy benefits managers (PBMs) to provide information about their business practices. In “The FTC’s New Investigation of PBMs,” Consultant Jessica Tinor provides some of the context necessary to understand the FTC’s concerns, specifically about rising consumer drug prices. She gives an overview of the prescription drug financing and distribution industry, explains the role of PMBs within that network, and discusses PBM incentives and how those could ultimately influence spending.

Read the article here (membership required).